Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02233101 · ClinicalTrials.gov registry record · NA
Oral vs. Intravenous TXA Study Proposal: TJA
A NA study of Blood Loss After Primary Total Joint Arthroplasty and Need for Blood Transfusion After Total Joint Arthroplasty, sponsored by Rush University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 167
- Enrollment target
- 1
- Study location
NCT02233101: Completed NA study of Blood Loss After Primary Total Joint Arthroplasty and Need for Blood Transfusion After Total Joint Arthroplasty, sponsored by Rush University Medical Center.
NCT02233101 is a NA study of Blood Loss After Primary Total Joint Arthroplasty and Need for Blood Transfusion After Total Joint Arthroplasty that has completed, run by Rush University Medical Center. The registered enrollment target is 167 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02233101, a NA study of Blood Loss After Primary Total Joint Arthroplasty and Need for Blood Transfusion After Total Joint Arthroplasty, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 167 participants
- Enrollment target
- 1
- Study location
Study Summary
Purpose: Examine oral and intravenous Tranexamic Acid (TXA) to determine whether or not the different routes of drug administration are equivalent in terms of post-operative reduction in hemoglobin, number of transfusions, and post-operative blood loss following TJA surgery. Hypothesis: Oral and intravenous TXA are equivalent routes of drug administration.
Primary Outcome
Patient hemoglobin will be measured during and after surgery for the first 24 hours to determine if a blood transfusion is indicated.
Conditions Studied
Interventions
- DRUG Oral Tranexamic Acid
- DRUG Intravenous Tranexamic Acid
Study Locations (1)
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-08 |
| Phase | NA |
What the finished NCT02233101 record still lists
NCT02233101 is an interventional study that assigns participants to a tested intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Blood Loss After Primary Total Joint Arthroplasty appearing as the primary indexed condition, and to 2 interventions - of which Oral Tranexamic Acid is the first listed.
NCT02233101 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02233101 about?
NCT02233101 is a clinical study titled "Oral vs. Intravenous TXA Study Proposal: TJA". Purpose: Examine oral and intravenous Tranexamic Acid (TXA) to determine whether or not the different routes of drug administration are equivalent in terms of post-operative reduction in hemoglobin, number of transfusions, and post-operative blood loss following TJA surgery. Hypothesis: Oral and in...
What is the current status of trial NCT02233101?
This trial is currently completed. It is a NA study. The enrollment target is 167 participants. The study started on 2014-06. Estimated completion is 2015-08.
What conditions does trial NCT02233101 study?
This clinical trial studies the following conditions: Blood Loss After Primary Total Joint Arthroplasty, Need for Blood Transfusion After Total Joint Arthroplasty.
What interventions are being tested in trial NCT02233101?
The interventions under investigation include: Oral Tranexamic Acid (DRUG), Intravenous Tranexamic Acid (DRUG).
Who is sponsoring clinical trial NCT02233101?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02233101 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02233101's enrollment target sits among peer trials
167 622nd of 2000 higher than 1,376 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04248283 · 167 participants · NA
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
- NCT04552509 · 167 participants · NA
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
- NCT05516277 · 167 participants · NA
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia